Making transparency happen

In the last few months, we’ve introduced new requirements for final reporting and automatic registration for Clinical Trials of Investigational Medicinal Products (CTIMPs), and next week new rules on deferring registration come into effect. This change is all part of Make it Public, our commitment to research transparency.

In this new blog Naho Yamazaki, Head of Policy and Engagement looks at the difference Make it Public is making.

Improving information for research participants

Think Ethics puts participants and ethics at the heart of health and social care research. This month we’re looking at how we can make sure people invited to take part in research receive clear and concise information which has been designed with and for participants. Read Leni Sivey’s blog. 

New combined review service for CTIMPs

Combined review with the Medicine and Healthcare products Regulatory Agency (MHRA) is the way all sponsors and applicants seek approval for new Clinical Trials of Investigational Medicinal Products (CTIMPs). 

In a joint blog, our Senior Development Manager, Catherine Blewett and Head of the MHRA Clinical Trials Unit, Martin O’Kane talked to MedCity about streamlining approvals and the benefits to the research community.

Read the blog

Celebrating the HRA Community

The HRA turned 10 on 1 December 2021. We’ve marked this by taking stock of how far we’ve come and looking to the future.

Our organisation is a community made up of our staff, Research Ethics Committee and Confidentiality Advisory Group members, the Public Involvement Network, technical assurance advisers and many others who work with us on a range of issues.

The vast majority of the HRA community are volunteers, so it was important to all of us to celebrate and thank the community for their work over the last ten years.

Read more